| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11864-018-0518-0 |
| P698 | PubMed publication ID | 29362920 |
| P2093 | author name string | Santosh Kesari | |
| Jerome J Graber | |||
| P2860 | cites work | Response of brain metastases from breast cancer to megestrol acetate: A case report | Q71833065 |
| A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors | Q73253467 | ||
| Response of leptomeningeal metastases from breast cancer to hormonal therapy | Q73986253 | ||
| Diagnosis and treatment of leptomeningeal metastases in a patient with renal carcinoma responding to 5-fluorouracil and gemcitabine | Q77914408 | ||
| Renal cell cancer presented with leptomeningeal carcinomatosis effectively treated with sorafenib | Q81235080 | ||
| Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01) | Q83411205 | ||
| Use of liposomal doxorubicin-cyclophosphamide combination in breast cancer patients with brain metastases: a monocentric retrospective study | Q87203725 | ||
| Triple intrathecal therapy alone with omission of cranial radiation in children with acute lymphoblastic leukemia | Q87862166 | ||
| Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine | Q28346742 | ||
| Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation. a multicentre phase II study | Q33343704 | ||
| Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. | Q33386298 | ||
| Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker | Q33399073 | ||
| Teniposide for brain metastases of small-cell lung cancer: a phase II study. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group | Q33490636 | ||
| Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer | Q33503382 | ||
| Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial | Q33926135 | ||
| Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study | Q34658082 | ||
| A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer | Q34960037 | ||
| A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer | Q35552072 | ||
| "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. | Q35570245 | ||
| Brain Metastases from Breast Cancer and Response to Treatment with Eribulin: A Case Series | Q35647947 | ||
| Neoplastic meningitis resulting from hematological malignancies: pharmacokinetic considerations and maximizing outcome | Q35799389 | ||
| Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma. | Q35845236 | ||
| Addition of Anti-Angiogenetic Therapy with Bevacizumab to Chemo- and Radiotherapy for Leptomeningeal Metastases in Primary Brain Tumors | Q36037733 | ||
| Leptomeningeal metastases: a RANO proposal for response criteria. | Q36236770 | ||
| Surgical Ventricular Entry is a Key Risk Factor for Leptomeningeal Metastasis of High Grade Gliomas | Q36346166 | ||
| Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. | Q36372466 | ||
| Durable Clinical Benefit of Pertuzumab in a Young Patient with BRCA2 Mutation and HER2-Overexpressing Breast Cancer Involving the Brain | Q36855453 | ||
| Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors | Q36870131 | ||
| EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors | Q36893219 | ||
| A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies | Q37036934 | ||
| Chemotherapy for brain metastases in small-cell lung cancer | Q37087478 | ||
| Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). | Q37122287 | ||
| Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial | Q37187732 | ||
| Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma | Q37637737 | ||
| Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis | Q38099258 | ||
| Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study. | Q38221330 | ||
| Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer | Q38384492 | ||
| Intravenous thiotepa for treatment of breast cancer-related leptomeningeal carcinomatosis: case series | Q38491916 | ||
| Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial | Q38666574 | ||
| Stereotactic radiosurgery versus whole-brain radiotherapy after intracranial metastasis resection: a systematic review and meta-analysis | Q38667233 | ||
| Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. | Q38726649 | ||
| Palliative lumboperitoneal shunt for leptomeningeal metastasis-related hydrocephalus: A case series | Q38836659 | ||
| Leptomeningeal metastases of solid cancer. | Q38962528 | ||
| CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. | Q39628663 | ||
| Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer | Q40308252 | ||
| Nimotuzumab treatment and outcome analysis in patients with leptomeningeal metastasis from nonsmall cell lung cancer | Q40322474 | ||
| Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy | Q40329404 | ||
| Activity of T-DM1 in Her2-positive breast cancer brain metastases | Q41455800 | ||
| Bevacizumab preconditioning followed by Etoposide and Cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy | Q41473164 | ||
| Rapid complete response using intrathecal rituximab in a patient with leptomeningeal lymphomatosis due to mantle cell lymphoma | Q42107475 | ||
| ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis | Q42720819 | ||
| Isolated loss of hormonal receptors in leptomeningeal metastasis from estrogen receptor- and progesterone receptor-positive lobular breast cancer | Q43177612 | ||
| Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study | Q43522608 | ||
| Diagnostic and prognostic significance of flow cytometry immunophenotyping in patients with leptomeningeal carcinomatosis | Q43621058 | ||
| Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial | Q44442912 | ||
| Durable remission of leptomeningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection. | Q44514729 | ||
| Complete remission of a brain metastasis to third-line hormonal treatment with megestrol acetate | Q44664105 | ||
| Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone | Q44760519 | ||
| A new treatment paradigm: neoadjuvant radiosurgery before surgical resection of brain metastases with analysis of local tumor recurrence | Q44896047 | ||
| A case of brain metastases from breast cancer that responded to anastrozole monotherapy. | Q45996214 | ||
| A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis | Q46220695 | ||
| Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases | Q46229171 | ||
| Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C. | Q46344036 | ||
| Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis | Q47589146 | ||
| Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study. | Q47823015 | ||
| Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients? | Q47936468 | ||
| Liposomal cytarabine in neoplastic meningitis from primary brain tumors: a single institutional experience. | Q48112036 | ||
| Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib | Q48209869 | ||
| Prospective evaluation of the effect on initial brain metastases from small cell lung cancer of platinum-etoposide based induction chemotherapy followed by an alternating multidrug regimen | Q48236575 | ||
| Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study | Q48244398 | ||
| Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. | Q48249183 | ||
| Complement Component 3 Adapts the Cerebrospinal Fluid for Leptomeningeal Metastasis | Q48269323 | ||
| Effect of contrast dose and field strength in the magnetic resonance detection of brain metastases | Q48272562 | ||
| Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib | Q48297686 | ||
| Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. | Q48364394 | ||
| Tumor resection with carmustine wafer placement as salvage therapy after local failure of radiosurgery for brain metastasis. | Q48390621 | ||
| Carboplatin as second line treatment for recurrent or progressive brain metastases from small cell lung cancer | Q48390896 | ||
| Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study | Q48401064 | ||
| Effects of Postoperative Radiotherapy on Leptomeningeal Carcinomatosis or Dural Metastasis after Resection of Brain Metastases in Breast Cancer Patients | Q48443841 | ||
| The imaging and neuropathological effects of Bevacizumab (Avastin) in patients with leptomeningeal carcinomatosis | Q48518964 | ||
| Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer | Q48549160 | ||
| Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial | Q48594003 | ||
| Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis | Q48595709 | ||
| Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-Naïve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer | Q48737612 | ||
| Stereotactic radiosurgery for focal leptomeningeal disease in patients with brain metastases. | Q50627980 | ||
| Successful treatment with an anti-PD-1 antibody for progressing brain metastases in renal cell cancer. | Q52145713 | ||
| Proton therapy and helical tomotherapy result in reduced dose deposition to the pancreas in the setting of cranio-spinal irradiation for medulloblastoma: implications for reduced risk of diabetes mellitus in long-term survivors. | Q55460562 | ||
| A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis | Q68189748 | ||
| Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia | Q71092997 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 3 | |
| P577 | publication date | 2018-01-23 | |
| P1433 | published in | Current Treatment Options in Oncology | Q3510796 |
| P1476 | title | Leptomeningeal Metastases | |
| P478 | volume | 19 |
| Q99237709 | CAR T Cell Therapy for Pediatric Brain Tumors | cites work | P2860 |
Search more.